Search results
Showing 1651 to 1665 of 8929 results
Evidence-based recommendations on ribociclib (Kisqali) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic (secondary) breast cancer in adults.
Show all sections
NICE is unable to make a recommendation on tabelecleucel (Ebvallo) for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus. This is because Pierre Fabre Ltd did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA923
Evidence-based recommendations on glofitamab (Columvi) for treating relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic treatments.
Evidence-based recommendations on tisagenlecleucel (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under.
In development Reference number: GID-IPG10318 Expected publication date: 25 March 2026
In development Reference number: GID-NG10443 Expected publication date: 25 March 2026
In development Reference number: GID-IPG10404 Expected publication date: 25 March 2026
Surgical insertion of a catheter-based left ventricular microaxial flow pump for cardiogenic shock
In development Reference number: GID-IPG10461 Expected publication date: 25 March 2026
Topic prioritisation
Topic prioritisation
Topic prioritisation
Topic prioritisation
High linear energy transfer radiation for carbon ion beam therapy
Topic prioritisation
Fetoscopic tracheal occlusion (FETO) for severe congenital diaphragmatic hernia
Topic prioritisation